Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system

M. El-Ekiaby, M. A. Sayed, C. Caron, S. Burnouf, N. El-Sharkawy, H. Goubran, M. Radosevich, J. Goudemand, D. Blum, L. De Melo, V. Soulié, J. Adam, T. Burnouf

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0·2 μm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 ± 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0·2 μm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6·5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components. 

Original languageEnglish
Pages (from-to)48-61
Number of pages14
JournalTransfusion Medicine
Volume20
Issue number1
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Fingerprint

Detergents
von Willebrand Factor
Virus Inactivation
Blood Cell Count
Octoxynol
Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis
Glycophorin
Blood Component Removal
Proteins
Intravenous Injections
Gas Chromatography
Infertility
Adsorption
Blood Cells
Oils
High Pressure Liquid Chromatography
phthalic acid
Safety
Equipment and Supplies

Keywords

  • Blood establishments
  • Cryoprecipitate
  • FFP
  • Filtration
  • Plasma
  • Solvent-detergent
  • Viral inactivation

ASJC Scopus subject areas

  • Hematology

Cite this

Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. / El-Ekiaby, M.; Sayed, M. A.; Caron, C.; Burnouf, S.; El-Sharkawy, N.; Goubran, H.; Radosevich, M.; Goudemand, J.; Blum, D.; De Melo, L.; Soulié, V.; Adam, J.; Burnouf, T.

In: Transfusion Medicine, Vol. 20, No. 1, 02.2010, p. 48-61.

Research output: Contribution to journalArticle

El-Ekiaby, M, Sayed, MA, Caron, C, Burnouf, S, El-Sharkawy, N, Goubran, H, Radosevich, M, Goudemand, J, Blum, D, De Melo, L, Soulié, V, Adam, J & Burnouf, T 2010, 'Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system', Transfusion Medicine, vol. 20, no. 1, pp. 48-61. https://doi.org/10.1111/j.1365-3148.2009.00963.x
El-Ekiaby, M. ; Sayed, M. A. ; Caron, C. ; Burnouf, S. ; El-Sharkawy, N. ; Goubran, H. ; Radosevich, M. ; Goudemand, J. ; Blum, D. ; De Melo, L. ; Soulié, V. ; Adam, J. ; Burnouf, T. / Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. In: Transfusion Medicine. 2010 ; Vol. 20, No. 1. pp. 48-61.
@article{9d3bae96b3934aaa825d7a993760ca57,
title = "Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system",
abstract = "Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0·2 μm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 ± 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0·2 μm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6·5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components. ",
keywords = "Blood establishments, Cryoprecipitate, FFP, Filtration, Plasma, Solvent-detergent, Viral inactivation",
author = "M. El-Ekiaby and Sayed, {M. A.} and C. Caron and S. Burnouf and N. El-Sharkawy and H. Goubran and M. Radosevich and J. Goudemand and D. Blum and {De Melo}, L. and V. Souli{\'e} and J. Adam and T. Burnouf",
year = "2010",
month = "2",
doi = "10.1111/j.1365-3148.2009.00963.x",
language = "English",
volume = "20",
pages = "48--61",
journal = "Transfusion Medicine",
issn = "0958-7578",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system

AU - El-Ekiaby, M.

AU - Sayed, M. A.

AU - Caron, C.

AU - Burnouf, S.

AU - El-Sharkawy, N.

AU - Goubran, H.

AU - Radosevich, M.

AU - Goudemand, J.

AU - Blum, D.

AU - De Melo, L.

AU - Soulié, V.

AU - Adam, J.

AU - Burnouf, T.

PY - 2010/2

Y1 - 2010/2

N2 - Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0·2 μm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 ± 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0·2 μm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6·5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components. 

AB - Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0·2 μm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 ± 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0·2 μm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6·5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components. 

KW - Blood establishments

KW - Cryoprecipitate

KW - FFP

KW - Filtration

KW - Plasma

KW - Solvent-detergent

KW - Viral inactivation

UR - http://www.scopus.com/inward/record.url?scp=74049149907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049149907&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3148.2009.00963.x

DO - 10.1111/j.1365-3148.2009.00963.x

M3 - Article

C2 - 19778318

AN - SCOPUS:74049149907

VL - 20

SP - 48

EP - 61

JO - Transfusion Medicine

JF - Transfusion Medicine

SN - 0958-7578

IS - 1

ER -